Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2)

John J. McGuire, Christopher Triggle

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The intercellular interactions of endothelial and vascular smooth muscle cells are interesting to many scientists who seek to develop new drugs to treat cardiovascular diseases. Of particular interest is the regulation of blood flow by the paracrine actions of the endothelium on the underlying vascular smooth muscle cells of blood vessels. The development and further understanding of drugs that mimic or potentiate endothelial-derived factors, in particular vasodilators such as nitric oxide (NO), have proved to be of therapeutic benefit (e.g., sildenafil, nitroglycerin). On the other hand, endothelial-derived proinflammatory substances are released in response to tissue insult or during the progression of vascular diseases such as atherosclerosis. Proteinase-activated receptor 2 (PAR2) represents a novel target for vascular biology because of 1) its unique mechanism of activation by proteinases, 2) questions regarding the identity of the endogenous agonist(s), and 3) its apparent multiple activities in the vasculature. Whether it will be agonists or antagonists of PAR2 that will serve as the basis for a new class of therapeutic agents for the treatment of vascular diseases is an open question for further research and drug development.

Original languageEnglish
Pages (from-to)14-19
Number of pages6
JournalDrug Development Research
Volume60
Issue number1
DOIs
Publication statusPublished - 1 Sep 2003
Externally publishedYes

Fingerprint

PAR-2 Receptor
Blood Vessels
Vascular Diseases
Vascular Smooth Muscle
Smooth Muscle Myocytes
Muscle
Cells
Pharmaceutical Preparations
Nitroglycerin
Blood vessels
Vasodilator Agents
Endothelium
Atherosclerosis
Nitric Oxide
Blood
Peptide Hydrolases
Cardiovascular Diseases
Therapeutics
Chemical activation
Tissue

Keywords

  • EDHF
  • Endothelium
  • Nitric oxide
  • PAR
  • Vascular smooth muscle

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2). / McGuire, John J.; Triggle, Christopher.

In: Drug Development Research, Vol. 60, No. 1, 01.09.2003, p. 14-19.

Research output: Contribution to journalReview article

@article{dc74cac4faac4c46a56d8798ea2d11d2,
title = "Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2)",
abstract = "The intercellular interactions of endothelial and vascular smooth muscle cells are interesting to many scientists who seek to develop new drugs to treat cardiovascular diseases. Of particular interest is the regulation of blood flow by the paracrine actions of the endothelium on the underlying vascular smooth muscle cells of blood vessels. The development and further understanding of drugs that mimic or potentiate endothelial-derived factors, in particular vasodilators such as nitric oxide (NO), have proved to be of therapeutic benefit (e.g., sildenafil, nitroglycerin). On the other hand, endothelial-derived proinflammatory substances are released in response to tissue insult or during the progression of vascular diseases such as atherosclerosis. Proteinase-activated receptor 2 (PAR2) represents a novel target for vascular biology because of 1) its unique mechanism of activation by proteinases, 2) questions regarding the identity of the endogenous agonist(s), and 3) its apparent multiple activities in the vasculature. Whether it will be agonists or antagonists of PAR2 that will serve as the basis for a new class of therapeutic agents for the treatment of vascular diseases is an open question for further research and drug development.",
keywords = "EDHF, Endothelium, Nitric oxide, PAR, Vascular smooth muscle",
author = "McGuire, {John J.} and Christopher Triggle",
year = "2003",
month = "9",
day = "1",
doi = "10.1002/ddr.10314",
language = "English",
volume = "60",
pages = "14--19",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2)

AU - McGuire, John J.

AU - Triggle, Christopher

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The intercellular interactions of endothelial and vascular smooth muscle cells are interesting to many scientists who seek to develop new drugs to treat cardiovascular diseases. Of particular interest is the regulation of blood flow by the paracrine actions of the endothelium on the underlying vascular smooth muscle cells of blood vessels. The development and further understanding of drugs that mimic or potentiate endothelial-derived factors, in particular vasodilators such as nitric oxide (NO), have proved to be of therapeutic benefit (e.g., sildenafil, nitroglycerin). On the other hand, endothelial-derived proinflammatory substances are released in response to tissue insult or during the progression of vascular diseases such as atherosclerosis. Proteinase-activated receptor 2 (PAR2) represents a novel target for vascular biology because of 1) its unique mechanism of activation by proteinases, 2) questions regarding the identity of the endogenous agonist(s), and 3) its apparent multiple activities in the vasculature. Whether it will be agonists or antagonists of PAR2 that will serve as the basis for a new class of therapeutic agents for the treatment of vascular diseases is an open question for further research and drug development.

AB - The intercellular interactions of endothelial and vascular smooth muscle cells are interesting to many scientists who seek to develop new drugs to treat cardiovascular diseases. Of particular interest is the regulation of blood flow by the paracrine actions of the endothelium on the underlying vascular smooth muscle cells of blood vessels. The development and further understanding of drugs that mimic or potentiate endothelial-derived factors, in particular vasodilators such as nitric oxide (NO), have proved to be of therapeutic benefit (e.g., sildenafil, nitroglycerin). On the other hand, endothelial-derived proinflammatory substances are released in response to tissue insult or during the progression of vascular diseases such as atherosclerosis. Proteinase-activated receptor 2 (PAR2) represents a novel target for vascular biology because of 1) its unique mechanism of activation by proteinases, 2) questions regarding the identity of the endogenous agonist(s), and 3) its apparent multiple activities in the vasculature. Whether it will be agonists or antagonists of PAR2 that will serve as the basis for a new class of therapeutic agents for the treatment of vascular diseases is an open question for further research and drug development.

KW - EDHF

KW - Endothelium

KW - Nitric oxide

KW - PAR

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=0041817717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041817717&partnerID=8YFLogxK

U2 - 10.1002/ddr.10314

DO - 10.1002/ddr.10314

M3 - Review article

VL - 60

SP - 14

EP - 19

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 1

ER -